Heather VanderMeulen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Heather VanderMeulen has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
Chantal Armali
Precision Diagnostics and Therapeutics Program Sunnybrook Health Sciences Centre Toronto Ontario Canada
4 shared publications- Yulia Lin
Precision Diagnostics and Therapeutics Program Sunnybrook Health Sciences Centre Toronto Ontario Canada
4 shared publications - Akash Gupta
Department of Medicine and Laboratory Medicine and Pathobiology University of Toronto Toronto Canada
3 shared publications Harley Meirovich
Precision Diagnostics and Therapeutics Program Sunnybrook Health Sciences Centre Toronto Ontario Canada
3 shared publicationsJeannie Callum
Sunnybrook Health Sciences Centre, Toronto, ON; Department of Pathology and Molecular Medicine, Kingston Health Sciences Centre and Queen's University, Kingston, ON
3 shared publicationsAmie Malkin
Precision Diagnostics and Therapeutics Program Sunnybrook Health Sciences Centre Toronto Ontario Canada
2 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Wiley in Transfusion
Blocking FcγRI and FcγRIII reduces RBC phagocytosis induced by patient‐derived anti‐E and anti‐K alloantibodies in vitro
Introduction/Objectives: Red blood cell (RBC) alloantibodies can cause hemolytic transfusion reactions and complicate compatible blood provision. Although antibody‐opsonized RBCs are thought to be cleared partly through macrophage Fcγ receptor‐mediated phagocytosis, the Fcγ receptors involved in phagocytosis induced by non‐D alloantibodies remain incompletely defined. Design and Methods: RBCs were sensitized with WHO anti‐E or anti‐C typing sera, or with plasma/serum from patients alloimmunized against RhE or K. Phagocytosis was assessed using THP‐1‐CD16A macrophages expressing FcγRI, FcγRIIA, and FcγRIII. Receptor involvement was evaluated using receptor‐specific deglycosylated blocking monoclonal antibodies. Results: RBCs sensitized with WHO anti‐E or anti‐C sera, or with patient‐derived anti‐E or anti‐K alloantibodies, were phagocytosed by THP‐1‐CD16A macrophages. FcγRI or FcγRIII blockade reduced phagocytosis, although the magnitude of inhibition varied by antibody source and individual patient sample. FcγRIIA blockade produced little or no significant reduction across the conditions tested. Combined FcγRI and FcγRIII blockade produced the greatest inhibition with WHO reference sera, although inhibition was not fully additive. Patient‐derived anti‐E and anti‐K samples showed a similar pattern. Conclusions: These findings support a functional contribution of FcγRI and FcγRIII to alloantibody‐mediated RBC phagocytosis in this in vitro macrophage model, while suggesting a limited role for FcγRIIA under these experimental conditions.
- 26 October 2026
- Published by Wiley in Transfusion
Open AccessBlocking FcγRI and FcγRIII reduces RBC phagocytosis induced by patient‐derived anti‐E and anti‐K alloantibodies in vitro
Introduction/Objectives: Red blood cell (RBC) alloantibodies can cause hemolytic transfusion reactions and complicate compatible blood provision. Although antibody‐opsonized RBCs are thought to be cleared partly through macrophage Fcγ receptor‐mediated phagocytosis, the Fcγ receptors involved in phagocytosis induced by non‐D alloantibodies remain incompletely defined. Design and Methods: RBCs were sensitized with WHO anti‐E or anti‐C typing sera, or with plasma/serum from patients alloimmunized against RhE or K. Phagocytosis was assessed using THP‐1‐CD16A macrophages expressing FcγRI, FcγRIIA, and FcγRIII. Receptor involvement was evaluated using receptor‐specific deglycosylated blocking monoclonal antibodies. Results: RBCs sensitized with WHO anti‐E or anti‐C sera, or with patient‐derived anti‐E or anti‐K alloantibodies, were phagocytosed by THP‐1‐CD16A macrophages. FcγRI or FcγRIII blockade reduced phagocytosis, although the magnitude of inhibition varied by antibody source and individual patient sample. FcγRIIA blockade produced little or no significant reduction across the conditions tested. Combined FcγRI and FcγRIII blockade produced the greatest inhibition with WHO reference sera, although inhibition was not fully additive. Patient‐derived anti‐E and anti‐K samples showed a similar pattern. Conclusions: These findings support a functional contribution of FcγRI and FcγRIII to alloantibody‐mediated RBC phagocytosis in this in vitro macrophage model, while suggesting a limited role for FcγRIIA under these experimental conditions.
- Open Access
- 29 September 2026
- Published by Wiley in Transfusion
- Vol. 66 (11) , 2373-2384
Mapping obstetric biobanks: A scoping review highlighting gaps in the study of alloimmunized pregnancies
Background: Maternal red cell alloimmunization can cause hemolytic disease of the fetus and newborn (HDFN), yet prediction of disease severity remains limited. Biobanks that link pregnancy biospecimens with clinical and laboratory data could accelerate translational research; however, the landscape of relevant obstetric biobanks has not been mapped. Study Design and Methods: We conducted a scoping review following Joanna Briggs Institute methodology. MEDLINE, Embase, and CENTRAL were searched from January 2005 to May 20, 2025 for publications describing the establishment, structure, or operation of obstetric biobanks. Abstract screening, text review, and data extraction were conducted in duplicate. Findings were synthesized narratively. Results: Of 2482 records screened, 29 publications met inclusion criteria, representing 21 unique biobanks across 18 countries and 6 continents. Most were conducted in high‐income countries ( n = 13) and were multicenter ( n = 17). Biobanks primarily focused on environmental and genetic influences on development ( n = 14) and pregnancy outcomes ( n = 7), with no identified biobanks dedicated to alloimmunization. The types of maternal biospecimens collected varied, including whole blood ( n = 19), plasma ( n = 18), serum ( n = 16), and urine ( n = 16), with frequent collection of placental tissue ( n = 14) and cord blood ( n = 16). All biobanks incorporated maternal clinical variables ( n = 21), whereas paternal ( n = 10) and laboratory ( n = 9) variables were less common. Only one biobank explicitly collected immunohematology variables (e.g., RhD status and maternal alloantibodies). Conclusion: Obstetric biobanks have the potential to accelerate discovery in alloimmunized pregnancies, but existing biobanks rarely capture immunohematologic variables. Integrating standardized immunohematology variables and paired maternal‐fetal‐paternal sampling into future initiatives could facilitate translational research on alloimmunization and HDFN.
- 29 September 2026
- Published by Wiley in Transfusion
- Vol. 66 (11) , 2373-2384
Open AccessMapping obstetric biobanks: A scoping review highlighting gaps in the study of alloimmunized pregnancies
Background: Maternal red cell alloimmunization can cause hemolytic disease of the fetus and newborn (HDFN), yet prediction of disease severity remains limited. Biobanks that link pregnancy biospecimens with clinical and laboratory data could accelerate translational research; however, the landscape of relevant obstetric biobanks has not been mapped. Study Design and Methods: We conducted a scoping review following Joanna Briggs Institute methodology. MEDLINE, Embase, and CENTRAL were searched from January 2005 to May 20, 2025 for publications describing the establishment, structure, or operation of obstetric biobanks. Abstract screening, text review, and data extraction were conducted in duplicate. Findings were synthesized narratively. Results: Of 2482 records screened, 29 publications met inclusion criteria, representing 21 unique biobanks across 18 countries and 6 continents. Most were conducted in high‐income countries ( n = 13) and were multicenter ( n = 17). Biobanks primarily focused on environmental and genetic influences on development ( n = 14) and pregnancy outcomes ( n = 7), with no identified biobanks dedicated to alloimmunization. The types of maternal biospecimens collected varied, including whole blood ( n = 19), plasma ( n = 18), serum ( n = 16), and urine ( n = 16), with frequent collection of placental tissue ( n = 14) and cord blood ( n = 16). All biobanks incorporated maternal clinical variables ( n = 21), whereas paternal ( n = 10) and laboratory ( n = 9) variables were less common. Only one biobank explicitly collected immunohematology variables (e.g., RhD status and maternal alloantibodies). Conclusion: Obstetric biobanks have the potential to accelerate discovery in alloimmunized pregnancies, but existing biobanks rarely capture immunohematologic variables. Integrating standardized immunohematology variables and paired maternal‐fetal‐paternal sampling into future initiatives could facilitate translational research on alloimmunization and HDFN.
- Open Access
- 15 July 2025
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 47 (9) , 103034
Transfusion Testing During Routine Pregnancies: Consensus Recommendations from a Modified Delphi Process
- 15 July 2025
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 47 (9) , 103034
Open AccessTransfusion Testing During Routine Pregnancies: Consensus Recommendations from a Modified Delphi Process
- Open Access
- 15 July 2025
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 47 (9) , 103035
Replacing Iron and Preventing Anemia in Pregnant patients of Limited Economic means (RIPPLE): The Impact of Funding Iron Supplementation in Pregnancy
- 15 July 2025
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 47 (9) , 103035
Open AccessReplacing Iron and Preventing Anemia in Pregnant patients of Limited Economic means (RIPPLE): The Impact of Funding Iron Supplementation in Pregnancy
- Open Access
- 5 June 2025
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 47 (8) , 102953
Ferric Derisomaltose Versus Iron Sucrose in Pregnancy (FLIP): A Retrospective Observational Study on Outpatient Intravenous Iron Infusion Capacity
- 5 June 2025
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 47 (8) , 102953
Open AccessFerric Derisomaltose Versus Iron Sucrose in Pregnancy (FLIP): A Retrospective Observational Study on Outpatient Intravenous Iron Infusion Capacity
- Open Access
- 3 October 2024
- Published by Wiley in Transfusion
- Vol. 64 (11) , 2043-2048
Reducing unnecessary outpatient group and screen testing at a regional cancer center
Background: Unnecessary group and screens (G&S) can lead to unnecessary antibody investigations, use of technologist time, and laboratory resources.Local Problem: A baseline audit at our institution identified that 25% of G&S from the cancer center were unnecessary. We aimed to reduce the ratio of monthly G&S to CBC samples processed from the cancer center by 10% (from 0.034 to 0.031) by January 2024.Methods: This represents an interrupted time series design from November 2022 to January 2024. Using Plan Do Study Act (PDSA) cycles, we aimed to increase the use of an existing reflex testing system, termed “do not test.” When this option is selected, the blood bank will only process the G&S sample if specific CBC criteria are met (e.g., hemoglobin p < .0001) and the ratio of G&S to CBC specimens improved from 0.034 to 0.028, exceeding the target of 0.031. We noted an improvement in the appropriateness of G&S orders from 75% at baseline (n = 20) to 97.5% (n = 80) post intervention (p = .003).Conclusions: We describe an effective strategy to improve G&S utilization at our institution's cancer center using a reflex testing system.
- 3 October 2024
- Published by Wiley in Transfusion
- Vol. 64 (11) , 2043-2048
Open AccessReducing unnecessary outpatient group and screen testing at a regional cancer center
Background: Unnecessary group and screens (G&S) can lead to unnecessary antibody investigations, use of technologist time, and laboratory resources.Local Problem: A baseline audit at our institution identified that 25% of G&S from the cancer center were unnecessary. We aimed to reduce the ratio of monthly G&S to CBC samples processed from the cancer center by 10% (from 0.034 to 0.031) by January 2024.Methods: This represents an interrupted time series design from November 2022 to January 2024. Using Plan Do Study Act (PDSA) cycles, we aimed to increase the use of an existing reflex testing system, termed “do not test.” When this option is selected, the blood bank will only process the G&S sample if specific CBC criteria are met (e.g., hemoglobin p < .0001) and the ratio of G&S to CBC specimens improved from 0.034 to 0.028, exceeding the target of 0.031. We noted an improvement in the appropriateness of G&S orders from 75% at baseline (n = 20) to 97.5% (n = 80) post intervention (p = .003).Conclusions: We describe an effective strategy to improve G&S utilization at our institution's cancer center using a reflex testing system.
- 1 May 2021
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 43 (5) , 665
Iron deficiency and anemia in pregnancy: a health equity issue
- 1 May 2021
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 43 (5) , 665
Iron deficiency and anemia in pregnancy: a health equity issue
- Open Access
- 26 July 2019
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 3 (4) , 733-740
The experience of postpartum bleeding in women with inherited bleeding disorders
- 26 July 2019
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 3 (4) , 733-740
Open AccessThe experience of postpartum bleeding in women with inherited bleeding disorders
- 23 September 2016
- Published by SAGE Publications in Clinical Pediatrics
- Vol. 56 (7) , 627-633
A 10-Year Review of Necrotizing Fasciitis in the Pediatric Population: Delays to Diagnosis and Management
Objective. To assess the promptness and appropriateness of management in pediatric cases of necrotizing fasciitis (NF). Methods. A retrospective chart review examined cases of pediatric NF treated at a pediatric tertiary care center over a 10-year period. Results. Twelve patients were identified over the 10-year period. The median (25th to 75th centile) times to appropriate antibiotic administration, infectious disease consults, surgical consults and debridement surgeries were 2.6 (2.1-3.2), 7.7 (3.4-24.4), 4.6 (1.7-21.0), and 22.1 (10.3-28.4) hours following assessment at triage. The initial antibiotic(s) administered covered the causative organism in 9 of 12 cases. The median (25th to 75th centile) length of hospital stay was 21 (14.0-35.5) days. Conclusions. The large variability in the care of these patients speaks to the range of their presenting symptomatology. The lack of a standardized approach to the pediatric patient with suspected NF results in delays in management and suboptimal antibiotic choice.
- 23 September 2016
- Published by SAGE Publications in Clinical Pediatrics
- Vol. 56 (7) , 627-633
A 10-Year Review of Necrotizing Fasciitis in the Pediatric Population: Delays to Diagnosis and Management
Objective. To assess the promptness and appropriateness of management in pediatric cases of necrotizing fasciitis (NF). Methods. A retrospective chart review examined cases of pediatric NF treated at a pediatric tertiary care center over a 10-year period. Results. Twelve patients were identified over the 10-year period. The median (25th to 75th centile) times to appropriate antibiotic administration, infectious disease consults, surgical consults and debridement surgeries were 2.6 (2.1-3.2), 7.7 (3.4-24.4), 4.6 (1.7-21.0), and 22.1 (10.3-28.4) hours following assessment at triage. The initial antibiotic(s) administered covered the causative organism in 9 of 12 cases. The median (25th to 75th centile) length of hospital stay was 21 (14.0-35.5) days. Conclusions. The large variability in the care of these patients speaks to the range of their presenting symptomatology. The lack of a standardized approach to the pediatric patient with suspected NF results in delays in management and suboptimal antibiotic choice.
- 2 June 2016
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 32 (1) , 146-153
A phenotype of IGFBP‐3 knockout mice revealed by dextran sulfate‐induced colitis
Background and Aim: Insulin‐like growth factor‐1 (IGF‐1) bioactivity has been shown to be attenuated by insulin‐like growth factor binding protein‐3 (IGFBP‐3), one of six IGF‐binding proteins. While prior work revealed no major phenotype associated with IGFBP‐3 knockout mice, we explored the possibility that a phenotype could be revealed under specific conditions of gastrointestinal stress.Methods: The dextran sodium sulfate (DSS) murine model of ulcerative colitis was used for this study.Results: Insulin‐like growth factor binding protein‐3 knockout mice had significantly reduced colitis on exposure to DSS as measured by lower levels of pro‐inflammatory cytokines IL‐6 (P < 0.0001), TNF‐α (P = 0.0035), and IL‐1β (P = 0.0112), reduced weight loss (P < 0.0001), reduced myeloperoxidase activity (P = 0.0025), and maintenance of colorectal length (P < 0.05), all relative to wild‐type mice exposed to DSS. IGFBP‐3 knockout mice also exhibited increased colon epithelial cell proliferation (P < 0.0001) following DSS exposure. Semi‐quantitative immunohistochemistry showed greater IGF‐1 receptor activation in colon epithelial cells of IGFBP‐3 knockout mice compared with control mice following DSS exposure.Conclusion: Our data demonstrate that IGFBP‐3 influences severity of DSS‐induced colitis. The observations suggest that in the absence of IGFBP‐3, enhanced IGF bioactivity leads to increased epithelial proliferation and mucosal barrier repair, thereby lessening inflammation.
- 2 June 2016
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 32 (1) , 146-153
A phenotype of IGFBP‐3 knockout mice revealed by dextran sulfate‐induced colitis
Background and Aim: Insulin‐like growth factor‐1 (IGF‐1) bioactivity has been shown to be attenuated by insulin‐like growth factor binding protein‐3 (IGFBP‐3), one of six IGF‐binding proteins. While prior work revealed no major phenotype associated with IGFBP‐3 knockout mice, we explored the possibility that a phenotype could be revealed under specific conditions of gastrointestinal stress.Methods: The dextran sodium sulfate (DSS) murine model of ulcerative colitis was used for this study.Results: Insulin‐like growth factor binding protein‐3 knockout mice had significantly reduced colitis on exposure to DSS as measured by lower levels of pro‐inflammatory cytokines IL‐6 (P < 0.0001), TNF‐α (P = 0.0035), and IL‐1β (P = 0.0112), reduced weight loss (P < 0.0001), reduced myeloperoxidase activity (P = 0.0025), and maintenance of colorectal length (P < 0.05), all relative to wild‐type mice exposed to DSS. IGFBP‐3 knockout mice also exhibited increased colon epithelial cell proliferation (P < 0.0001) following DSS exposure. Semi‐quantitative immunohistochemistry showed greater IGF‐1 receptor activation in colon epithelial cells of IGFBP‐3 knockout mice compared with control mice following DSS exposure.Conclusion: Our data demonstrate that IGFBP‐3 influences severity of DSS‐induced colitis. The observations suggest that in the absence of IGFBP‐3, enhanced IGF bioactivity leads to increased epithelial proliferation and mucosal barrier repair, thereby lessening inflammation.